Acceleron Announces Pricing of Initial Public Offering

  Acceleron Announces Pricing of Initial Public Offering

Business Wire

CAMBRIDGE, Mass. -- September 18, 2013

Acceleron Pharma, Inc. today announced the pricing of its initial public
offering of 5,580,000 shares of common stock at a public offering price of
$15.00 per share, before underwriting discounts. In addition, Acceleron has
granted the underwriters a 30-day option to purchase up to an additional
837,000 shares of common stock at the public offering price, less underwriting
discounts. Separately, in a concurrent, side-by-side private placement,
Acceleron’s collaboration partner, Celgene Corporation (NASDAQ:CELG), has
agreed to purchase 666,667 shares of common stock from Acceleron at the public
offering price. Acceleron’s common stock has been approved for listing on the
NASDAQ Global Market and is expected to begin trading under the ticker symbol
“XLRN” on September 19, 2013.

Citigroup and Leerink Swann are acting as joint book-running managers for the
offering. Piper Jaffray & Co. is acting as lead manager and JMP Securities LLC
is acting as co-manager for the offering.

A registration statement relating to these securities was declared effective
on September 18, 2013. The offering will be made only by means of a
prospectus, copies of which may be obtained from Citigroup, c/o Broadridge
Financial Solutions, 1155 Long Island Avenue, Edgewood, NY, 11717, or by email
at, or by phone at 800-831-9146; or Leerink Swann,
Attention: Syndicate Department, One Federal Street, 37^th Floor, Boston, MA,
02110, or by email at, or by phone at 800-808-7525.

This press release shall not constitute an offer to sell or the solicitation
of an offer to buy, nor shall there be any sale of, these securities in any
state or jurisdiction in which such offer, solicitation or sale would be
unlawful prior to the registration or qualification under the securities laws
of such state or jurisdiction.

About Acceleron

Acceleron is a clinical stage biopharmaceutical company focused on the
discovery, development and commercialization of novel protein therapeutics for
cancer and rare diseases. The company is a leader in understanding the biology
of the Transforming Growth Factor-Beta (TGF-β) protein superfamily, a large
and diverse group of molecules that are key regulators in the growth and
repair of tissues throughout the human body, and in targeting these pathways
to develop important new medicines. Acceleron has built a highly productive
R&D platform that has generated innovative clinical and preclinical protein
therapeutic candidates with novel mechanisms of action. These protein
therapeutic candidates have the potential to significantly improve clinical
outcomes for patients with cancer and rare diseases.


Acceleron Pharma
Kevin McLaughlin, 617-649-9204
Chief Financial Officer
Suda Communications LLC
Maureen L. Suda, 585-387-9248
Press spacebar to pause and continue. Press esc to stop.